Menu
Menu
Newsletter
Menu
Newsletter
Immutep
Biotech Stocks
Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?
Recce secures A$85m R&D backing as Phase 3 nears Recce Pharmaceuticals (ASX: RCE) hit a one-week high after landing an A$85 million Advanced Overseas Finding from AusIndustry. This ruling is among the largest reported under Australia’s R&D Tax Incentive program. The finding means Recce's international clinical programs now qualify for the government's 43.5% tax rebate…
December 17, 20250Comments
Cynata
Biotech Stocks
Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?
Cynata Therapeutics (ASX: CYP) has completed patient enrollment in its Phase 2 clinical trial of a stem cell treatment called CYP-001 for acute graft versus host disease (aGvHD), a potentially life-threatening complication that affects up to 50 per cent of bone marrow transplant patients. With 65 participants now enrolled across clinical centres in the US,…
December 16, 20250Comments
Medallion
Gold Stocks
Medallion Metals’ $60M War Chest Sets Up 2026 Production Push- Is the Stock a Buy?
Medallion’s A$60M Raise Sets Up a 2026 Production Push Medallion Metals (ASX: MM8) has secured an A$60 million funding package, with Lion Selection Group committing A$5 million to the raise. For investors watching the junior gold developer space, this backing from one of Australia's most respected resource-focused investment groups signals strong institutional conviction in the…
December 16, 20250Comments

the Kick-ass Multipurpose WordPress Theme

Investing in the Year of the Rat
2020, the Golden Year
Market trouble spots to avoid in 2020
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here